- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
Corcept Therapeutics submitted an NDA for relacorilant to the FDA and is evaluating it in combination with Roche's Avastin.
4 reports, 4 independent
Updated Jul 27
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 4
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Corcept Therapeutics submitted an NDA for relacorilant to the FDA and is evaluating it in combination with Roche's Avastin.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.FDA rejected Corcept Therapeutics' drug application for relacorilant.1 source
Corcept submitted NDA for relacorilant to FDA, evaluating it with Roche's Avastin.1 source
Keep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
- FDA
-
Corcept Therapeutics
American pharmaceutical company
-
Hoffmann-La Roche
Swiss healthcare company
Related events
- Corcept Therapeutics is seeking final approval from the European Commission for a cancer therapy already approved in the US market.
- Celcuity Inc. and Corcept Therapeutics are noted for developing targeted therapies in the United States.
- Kowa's New Drug Application (NDA) for drug K-911 was accepted by the FDA for review.
- Investor activity regarding Corcept Therapeutics, including RBC boosting holdings and Amundi buying, was disclosed via SEC filings.
Coverage
Newest first; wire copies grouped- financialcontent.comWhy Corcept (CORT) Stock Is Down Today
- ZacksCan Korlym Drive Corcept's Growth Through the Rest of 2025? Corcept Therapeutics’ CORT sole-marketed drug, Korlym (mifepristone), which is approved for treating Cushing's syndrome or endogenous hyper
- Insider MonkeyCanaccord Genuity Maintains a Buy on Corcept Therapeutics (CORT), Retains a $137 PT Corcept Therapeutics Incorporated (NASDAQ:CORT) is one of the most promising future stocks according to Wall Street
- Business WireCorcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer REDWOOD CITY, Calif., July 14, 2025--(BUSINESS WIRE)--Corcept Therapeutics Inc